Opinion/decision on a Paediatric investigation plan (PIP): Xofluza, Baloxavir marboxil, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Infectious diseases, PIP number: P/0098/2023

Vaccine Monitoring Platform: List of EMA-funded studies

Multi-stakeholder webinar on the HMA-EMA Catalogues of real-world data sources and studies, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 4 March 2024, 10:00 (CET) to 4 March 2024, 12:00 (CET)

Opinion/decision on a Paediatric investigation plan (PIP): Evkeeza, Evinacumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Endocrinology-Gynaecology-Fertility-Metabolism, PIP number: P/0087/2023

Deadlines for submission of applications for orphan medicinal product designation to the EMA and corresponding COMP timetable for valid applications - 2024-2025

Meeting Report of the second Listen and Learn Focus Group (LLFG) meeting of the Quality Innovation Group (QIG)

Final Minutes – HMA-EMA joint Big Data Steering Group teleconference - 30 January 2024

3Rs Working Party (3RsWP) plenary meeting – Public session on the 2024 work plan, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 20 March 2024, 09:00 (CET) to 20 March 2024, 10:00 (CET)

EMEA-003341-PIP01-22

EMEA-003342-PIP01-22